Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma



Cebon, Jonathan S, Gore, Martin, Thompson, John F, Davis, Ian D, McArthur, Grant A, Walpole, Euan, Smithers, Mark, Cerundolo, Vincenzo, Dunbar, P Rod, MacGregor, Duncan
et al (show 23 more authors) (2020) Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8 (1).

[img] Text
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX.pdf - OA Published Version

Download (2MB) | Preview
Item Type: Article
Uncontrolled Keywords: oncology, immunology, tumours, randomised trials, HLA
Depositing User: Symplectic Admin
Date Deposited: 21 May 2020 08:59
Last Modified: 03 Oct 2021 12:12
DOI: 10.1136/jitc-2019-000410
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3088188